Top

Published in:

01-06-2009 | Review

Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors

Authors: Kevin Kelly, Ronan Swords, Devalingam Mahalingam, Swaminathan Padmanabhan, Francis J. Giles

Published in: Targeted Oncology | Issue 2/2009

Abstract

Tyrosine kinase inhibitors (TKIs) have dramatically changed the treatment of chronic myeloid leukemia (CML) and are increasingly used in other malignancies. Despite the apparent selectivity of these agents significant side effects can occur mainly due to off target kinase inhibition. Clinical consequences of serosal inflammation, including pleural and pericardial effusions, have emerged as a frequent adverse event associated with dasatinib while occurring much less frequently during imatinib and nilotinib therapy. The pathogenesis is uncertain but may involve inhibition of platelet derived growth factor or expansion of cytotoxic T and natural killer cells. The development of serosal inflammation with dasatinib poses a significant challenge to physicians, as it cannot be predicted, the time of onset is variable, and management frequently requires repeat invasive procedures.

Druker BJ et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23):2408–2417CrossRefPubMed

Shah NP et al (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2(2):117–125CrossRefPubMed

Gorre ME et al (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293(5531):876–880CrossRefPubMed

Jabbour E et al (2007) Current and emerging treatment options in chronic myeloid leukemia. Cancer 109(11):2171–2181CrossRefPubMed

Kantarjian HM et al (2006) New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 145(12):913–923PubMed

Kantarjian H et al (2007) Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 109(12):5143–5150CrossRefPubMed

Talpaz M et al (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354(24):2531–2541CrossRefPubMed

Shah NP et al (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305(5682):399–401CrossRefPubMed

Nam S et al (2005) Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 65(20):9185–9189CrossRefPubMed

10.

Hochhaus A et al (2007) Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109(6):2303–2309CrossRefPubMed

11.

Shah NP et al (2008) Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 26(19):3204–3212CrossRefPubMed

12.

Quintas-Cardama A et al (2007) Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 25(25):3908–3914CrossRefPubMed

13.

Kantarjian HM et al (2007) Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 110(10):3540–3546CrossRefPubMed

14.

Bergeron A et al (2007) Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 176(8):814–818CrossRefPubMed

15.

de Lavallade H et al (2008) Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol 141(5):745–747CrossRefPubMed

16.

Kim D et al (2008) Pleural effusion in dasatinib-treated chronic myeloid leukemia patients after imatinib failure. ASH Annual Meeting Abstracts 112(11):4270

17.

Cortes J et al (2008) Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 22(12):2176–2183CrossRefPubMed

18.

Posadas EM et al (2007) A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. Cancer 110(2):309–317CrossRefPubMed

19.

Lombardo LJ et al (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47(27):6658–6661CrossRefPubMed

20.

Buchdunger E et al (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295(1):139–145PubMed

21.

Deininger MW (2008) Nilotinib. Clin Cancer Res 14(13):4027–4031CrossRefPubMed

22.

Heldin CH, Westermark B (1999) Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79(4):1283–1316PubMed

23.

Lindahl P et al (1997) Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 277(5323):242–245CrossRefPubMed

24.

Jayson GC et al (2005) Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol 23(5):973–981CrossRefPubMed

25.

Wilhelm SM et al (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7(10):3129–3140CrossRefPubMed

26.

Strumberg D et al (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12(4):426–437CrossRefPubMed

27.

Laird AD et al (2002) SU6668 inhibits Flk-1/KDR and PDGFR{beta} in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J 16(7):681–690PubMed

28.

Wallez Y et al (2007) Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site. Oncogene 26(7):1067–1077CrossRefPubMed

29.

Luton F et al (1999) The SRC family protein tyrosine kinase p62yes controls polymeric IgA transcytosis in vivo. Mol Cell 4(4):627–632CrossRefPubMed

30.

Rix U et al (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110(12):4055–4063CrossRefPubMed

31.

Matsuyama W et al (2005) Involvement of discoidin domain receptor 1 in the deterioration of pulmonary sarcoidosis. Am J Respir Cell Mol Biol 33(6):565–573CrossRefPubMed

32.

Sakamoto O et al (2001) Expression of discoidin domain receptor 1 tyrosine kinase on the human bronchial epithelium. Eur Respir J 17(5):969–974CrossRefPubMed

33.

Berg LJ et al (2005) Tec family kinases in T lymphocyte development and function. Annu Rev Immunol 23:549–600CrossRefPubMed

34.

Lindvall JM et al (2005) Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol Rev 203:200–215CrossRefPubMed

35.

Kawakami Y et al (1999) Functions of Bruton's tyrosine kinase in mast and B cells. J Leukoc Biol 65(3):286–290PubMed

36.

Mustjoki S et al (2008) Clonal expansion of T/NK-Cells during tyrosine kinase inhibitor dasatinib therapy. ASH Annual Meeting Abstracts 112(11):573

37.

Mustjoki S et al (2007) Clonal large granular lymphocyte (LGL) expansion associated with dasatinib therapy. ASH Annual Meeting Abstracts 110(11):2938

38.

Druker BJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344(14):1031–1037CrossRefPubMed

39.

le Coutre PD, 11 et al (2008) Occurrence of pleural/pericardial effusions in Ph + CML patients failing prior tyrosine kinase inhibitors (TKI) before starting nilotinib—retrospective analysis upon entry into the nilotinib compassionate use program. ASH Annual Meeting Abstracts 112:4271

40.

Breccia M et al (2005) Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib. Eur J Haematol 74(1):89–90CrossRefPubMed

41.

Barton JC et al (2002) Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia. Am J Hematol 71(2):139–140CrossRefPubMed

42.

Hazarika M et al (2008) Tasigna for chronic and accelerated phase Philadelphia chromosome—positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 14(17):5325–5331CrossRefPubMed

43.

Weisberg E et al (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7(2):129–141CrossRefPubMed

44.

Puttini M et al (2006) In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl + neoplastic cells. Cancer Res 66(23):11314–11322CrossRefPubMed

45.

Cortes J et al (2008) Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph + chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib. ASH Annual Meeting Abstracts 112(11):1098

46.

Hochhaus A et al (2008) Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22(6):1200–1206CrossRefPubMed

47.

Cortes J et al (2008) Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). ASH Annual Meeting Abstracts 112(11):182

48.

Rosti G et al (2008) High and early rates of cytogenetic and molecular response with nilotinib 800 mg daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: results of a phase II trial of the GIMEMA CML Working Party. ASH Annual Meeting Abstracts 112(11):181

49.

Stephens J et al (2007) The cost of managing pleural effusion associated with dasatinib in CML patients post imatinib failure. ASH Annual Meeting Abstracts 110(11):4586

50.

Hu Y et al (2004) Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 36(5):453–461CrossRefPubMed

51.

Cortes J et al (2006) Dasatinib (SPRYCEL®) in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in chronic phase (CML-CP). ASH Annual Meeting Abstracts 108(11):2161

Title: Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors
Authors: Kevin Kelly
Ronan Swords
Devalingam Mahalingam
Swaminathan Padmanabhan
Francis J. Giles
Publication date: 01-06-2009
Publisher: Springer-Verlag
Published in: Targeted Oncology / Issue 2/2009
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-009-0110-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

Indexing: the north face

Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?

The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents

Skin toxicities associated with epidermal growth factor receptor inhibitors

Renal toxicity of targeted therapies

QT interval prolongation among patients treated with angiogenesis inhibitors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer